Posted by Michael Wonder on 06 Dec 2017
FDA grants Genentech’s Avastin full approval for most aggressive form of brain cancer
5 December 2017 - Genentech announced today that the U.S. FDA has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease).
Avastin was previously granted provisional approval in this setting under the FDA's accelerated approval program.
This conversion to full approval was based on the totality of evidence of Avastin in glioblastoma, including data from the Phase III EORTC 26101 study. Avastin is now approved in the United States for nine distinct uses across six different types of cancer.
